Patent intelligence · US
US 11692018
TGF-β polypeptides
TGF-β polypeptides
Patent details — US 11692018
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 4, 2023
- Expiration
- Jun 29, 2043
- Applicant
- Cue Biopharma, Inc.
- Claims
- 23
- CPC classes
- A61K, A61K38/00, A61P, A61P37/00
Quick answer
US 11692018 (TGF-β polypeptides) is held by Cue Biopharma, Inc.. Status: granted. Granted Jul 4, 2023. Expires Jun 29, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cue Biopharma, Inc.
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61K, A61K38/00, A61P, A61P37/00, A61P37/06
More from Cue Biopharma, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421287
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 12257311
Multimeric T-cell modulatory polypeptides and methods of use thereof
granted -
US 12180258
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 12152061
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 12145973
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 12029782
MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof
granted -
US 12006348
T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
granted -
US 11993641
Methods for modulating an immune response
granted
Frequently asked questions
What is US patent 11692018?
US 11692018 (TGF-β polypeptides) is held by Cue Biopharma, Inc.. Status: granted. Granted Jul 4, 2023. Expires Jun 29, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11692018?
Cue Biopharma, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 30 pharmaceutical patents for this assignee.
When does US 11692018 expire?
Our index shows an expiration date of Jun 29, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.